Back to Search
PAUL ERBEN, DMD
DMD
Endodontics
NPI: 1265709281Individual
Specialties, Licenses & Credentials
EndodonticsPrimary
Dentist — Endodontics
Code: 1223E0200X
104593(CA)
Research & Publications (20)
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
PMID 19436196·Anticancer Drugs·2009
3-trial
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
PMID 19131187·Int J Radiat Oncol Biol Phys·2009
3-trial
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
PMID 19487385·J Clin Oncol·2009
3-trial
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
PMID 19006078·Genes Chromosomes Cancer·2009
5-case
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
PMID 19652056·J Clin Oncol·2009
3-trial
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
PMID 18223278·Haematologica·2008
4-observational
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
PMID 17943168·Leukemia·2008
4-observational
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
PMID 19028276·Int J Radiat Oncol Biol Phys·2008
8-other
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
PMID 18950453·Br J Haematol·2008
3-trial
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
PMID 18603549·Haematologica·2008
8-other
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
PMID 18367481·Haematologica·2008
8-other
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
PMID 18303987·Clin Chem Lab Med·2008
8-other
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
PMID 17613428·Lancet Oncol·2007
5-case
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
PMID 17597804·Leukemia·2007
8-other
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
PMID 17576939·Arch Dermatol·2007
5-case
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
PMID 17550857·Haematologica·2007
3-trial
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
PMID 17377585·Leukemia·2007
3-trial
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
PMID 17299092·Blood·2007
8-other
Resistance to targeted therapy in chronic myelogenous leukemia.
PMID 17292737·Semin Hematol·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 937 E MAIN ST STE 204
SANTA MARIA, CA 93454 - Phone
- (805) 349-2222
Quick Facts
- NPI
- 1265709281
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile